Benjamin Garmezy, MD, discusses how JNJ-6143 uses a novel RIPTAC mechanism to target AR and BRD4, potentially addressing resistance-associated genomic alterations in advanced prostate cancer.
The FDA has approved the PCR-based OncoMate MSI Dx Analysis System as a companion diagnostic to identify MSI-H solid tumors ...
During a live event, Theresa Medina, MD, and participants discussed how disease site, BRAF status, and prior therapy guide treatment selection in metastatic melanoma.
Kohei Shitara, MD, discusses HERIZON-GEA-01 findings and how to individualize first-line treatment for HER2-positive advanced ...
Oncologists discuss long-term ibrutinib use, cardiovascular risks with BTK inhibitors, and emerging fixed-duration acalabrutinib-venetoclax therapy in CLL.
Among patients surveyed, 92% preferred home-based treatment, while nationwide modeling projected substantial savings in ...
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization ...
The FDA accepted an sNDA for gedatolisib in PIK3CA-mutant HR+/HER2– advanced breast cancer based on the phase 3 VIKTORIA-1 ...
During a live event, Pedro Barata, MD, MSc, and participating oncologists discussed how efficacy, tolerability, and clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results